Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer

Ovarian Cancer Clinical Trial

Official title:

Single-Dose, Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Humanized Monoclonal Antibody 3S193 (90Y-hu3S193) in Patients With Advanced Ovarian Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00072410
• Other study ID #: CDR0000339682
• Secondary ID: MSKCC-03069LUD20
• Status: Completed
• Phase: Phase 1
• Start date: November 2003
• Est. completion date: November 15, 2006

Study information

• Verified date: October 2023
• Source: Ludwig Institute for Cancer Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. Giving radiolabeled monoclonal antibody directly into the abdominal cavity may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of giving radiolabeled monoclonal antibody therapy directly into the abdominal cavity in treating patients who have advanced ovarian epithelial cancer.

Description:

OBJECTIVES:

Primary

• Determine the safety and maximum tolerated dose of intraperitoneally (IP) administered yttrium-90 (90Y) radiolabeled monoclonal antibody (mAB) hu3S193 (90Y-hu3S193) in patients with advanced ovarian epithelial cancer.

Secondary

• Determine the localization and whole body and abdominal clearance of 90Y-hu3S193 using indium-111 (111In) radiolabeled hu3S193 and gamma camera imaging.

• Determine the serum pharmacokinetics of hu3S193 using gamma well counting.

• Determine the antibody response as measured by human anti-human antibody response (HAHA).

OUTLINE: This is a dose-escalation study of the yttrium-90 radiolabeled monoclonal antibody, 90Y-hu3S193.

Patients received technetium (99mTc-sulfur colloid) IP and underwent abdominal imaging on day

1. Provided the distribution of the 99mTC-sulfur colloid was deemed adequate, patients then received 90Y-hu3S193 IP. 111In-hu3S193 was also administered IP over 30 minutes on day 1 to enable gamma camera imaging. Within 3-5 hours after antibody administration, patients underwent whole body imaging and single-photon emission-computed tomography (SPECT) imaging of the abdomen and pelvis.

Cohorts of 3-6 patients were to receive escalating doses of 90Y-hu3S193 until the maximum tolerated dose (MTD) was determined. The MTD was defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients were to be followed every 3 months for at least 2 years and then every 6 months for up to 5 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: November 15, 2006
• Est. primary completion date: May 2005
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. Histologically confirmed non-mucinous ovarian adenocarcinoma.

2. Persistent or recurrent intraperitoneal cancer following platinum/taxane-based therapy for Stage 3 ovarian cancer.

3. Patients with residual disease < 2cm will be candidates for this study.

4. The following laboratory and clinical results within the last 2 weeks prior to study day 1:

Absolute neutrophil count (ANC) = 1.5 x 10^9/L; Platelet count = 100 x 10^9/L; Serum bilirubin = 2.0 mg/dL; Aspartate aminotransferase (AST) = 2.5 x upper limit of normal (ULN); Alanine aminotransferase (ALT) = 2.5 x ULN; Serum creatinine =2.0 mg/dL; Forced expiratory volume (FEV1) =60% of predicted; Forced vital capacity (FVC) =60% of predicted; Diffusion capacity =55% of predicted; Left ventricular ejection fraction (LVEF) =50%;

5. Karnofsky performance status = 70.

6. Before any trial-specific procedures or treatment can be performed, the patient or legally authorized guardian or representative must give witnessed written informed consent for participation in the trial.

7. Placement of an intra-abdominal catheter at the time of surgery.

Exclusion Criteria

1. Active parenchymal disease (i.e., Stage IV International Federation of Gynecology and Obstetrics (FIGO) classification).

2. Presence of symptomatic extra abdominal metastases.

3. Known central nervous system (CNS) tumor involvement.

4. Clinically significant heart disease (New York Heart Association Class III or IV).

5. ECG demonstrating clinically significant arrhythmias or evidence of prior myocardial infarction.

6. Other serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders that may limit the amount of antibody they can tolerate or render them ineligible for surgery.

7. Chronic inflammatory bowel disease.

8. Chemotherapy, biologic therapy, or immunotherapy within 4 weeks prior to enrollment.

9. Pregnancy or lactation.

10. Patients who are positive for human anti-human antibodies (HAHA) and/or who have received a murine monoclonal antibody.

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Ovarian Cancer
• Ovarian Neoplasms

Intervention

Biological:
• 90Y-hu3S193
Patients received a single dose of 10 mg of hu3S193 radiolabeled with the intended dose (mCi) of 90Y.
• 111In-hu3S193
Patients received a single dose of 5 mCi 111In-hu3S193 together with the 90Y-hu3S193.

Locations

Country	Name	City	State
United States	Memorial Sloan-Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Ludwig Institute for Cancer Research	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients With Dose-limiting Toxicities (DLTs)	All adverse events were graded according to the National Cancer Institute Common Toxicity Criteria (CTC) Scale (Version 2.0, published April 30, 1999). DLT was defined as: Any Grade 3 or greater non-hematological toxicity (except for alopecia, nausea, and vomiting, defined separately below); Any Grade alopecia; Grade 4 nausea or vomiting = 5 days duration.; Any Grade 4 hematological toxicity (except for toxicity of = 5 days duration without growth factor, platelet, or transfusion support). To be dose limiting, an adverse event must be definitely, probably, or possibly related to the administration of the investigational agent.	Up to day 56
Secondary	Clearance as Measured by the Half-life (T1/2) of the Elimination Phase	Serum samples were taken 5 min, 1 hour, and 2 hours after end of infusion, twice on study day 2, and daily on study days 3 to 7, 8, 15 and 22. Serum samples were analyzed in a gamma well counter. Elimination half-life (T1/2) was generated by fitting effective clearance to a monoexponential curve.	Up to 22 days
Secondary	Number of Patients With Human Anti-human Antibodies (HAHA) After Treatment	Blood samples were taken at baseline and on days15, 28 and 56. HAHA was measured by BIACORE.	Up to day 56